Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Gimv NV
  6. News
  7. Summary
    GIMB   BE0003699130

GIMV NV

(GIMB)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 10/21 07:14:26 am
55.6 EUR   +0.72%
10/04GIMV : Projective Group acquires Dutch consulting firm Mastermind
PU
10/02GIMV : Trends Talk met Koen Dejonckheere dd 02/10/21
PU
09/29GIMV : Jens Pohl the new CEO at Smart Battery Solutions
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gimv : partners with Apraxon to support the company's growth ambitions

04/14/2021 | 01:33am EDT

Gimv has completed its investment into the Apraxon Group, a leading homecare provider focusing on wound care services in Germany. This transaction is part of a joint growth plan with the company's founder and CEO Oliver Pokrzewinski, who will continue to be an important shareholder in the company.

Apraxon, (Hofbieber (DE) - apraxon.com), offers high quality wound care for (mostly elderly) people suffering from chronic wounds in a homecare setting. Typical wound indications include decubitus, diabetic foot or ulcus cruris. In providing this service, the company acts as an intermediary between patients, doctors, nursing services or homes and insurance companies.

Due to its high degree of specialization, Apraxon continuously provides high quality medical care and is able to tailor the treatment process according to each patient's individual needs. In a market with steadily increasing patient numbers, primarily driven by demographic change, specialized medical care is gaining in importance. Services provided are reimbursed by health insurance companies, for whom Apraxon has been a reliable partner for many years.

'I am convinced that Gimv is the right partner to realize the company's growth ambitions and expand Apraxon's footprint in Germany,' explains Oliver Pokrzewinski, Managing Director and CEO of Apraxon.

'Thanks to Apraxon's clear commitment to quality, highly qualified nursing staff and strongly digitised and scalable processes, we believe that Apraxon is the right platform to build a true leader in the German wound care market. We are very much looking forward to supporting Mr. Pokrzewinski and the entire Apraxon team in realising their ambitious growth plans,' says Philipp v. Hammerstein, Partner at Gimv in the Health & Care team in Munich.

The new investment marks Gimv's fifth acquisition in the German-speaking healthcare market over the last four years. Gimv currently has 23 participations in companies in the healthcare and life sciences sector. This acquisition further underpins Gimv's position as one of the most active European investors in the healthcare industry and its ambition to positively contribute to the United Nations Sustainable Development Goals of good health and well-being. The Gimv portfolio also includes several clinic and practice groups, as well as medical technology and biotech companies

Disclaimer

GIMV Investeringsmaatschappij Voor Vlanderen NV published this content on 14 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 April 2021 05:32:03 UTC.


© Publicnow 2021
All news about GIMV NV
10/04GIMV : Projective Group acquires Dutch consulting firm Mastermind
PU
10/02GIMV : Trends Talk met Koen Dejonckheere dd 02/10/21
PU
09/29GIMV : Jens Pohl the new CEO at Smart Battery Solutions
PU
09/29GIMV : Smart Battery Solutions holt mit Jens Pohl erfahrenen CEO an Bord und stellt sich f..
PU
09/16GIMV : Leads $60 Million Financing Round of Swiss Gene Therapy Company
MT
09/16GIMV : leads CHF55.5M ($61M) Series A financing in Anjarium Biosciences to develop novel n..
PU
09/16Anjarium Biosciences AG announced that it has received CHF 55.5 million in funding from..
CI
08/05GIMV : Projective Group acquires specialist data consultancy DTSQUARED
PU
07/29GIMV : Topas Therapeutics announces and extended Series B round with an additional € 18 mi..
PU
07/29GIMV : Topas Therapeutics announces and extended Series B round with an additional € 18 mi..
PU
More news
Financials
Sales 2021 331 M 385 M 385 M
Net income 2021 206 M 239 M 239 M
Net cash 2021 165 M 192 M 192 M
P/E ratio 2021 6,41x
Yield 2021 4,90%
Capitalization 1 470 M 1 712 M 1 711 M
EV / Sales 2020 7,43x
EV / Sales 2021 3,52x
Nbr of Employees 89
Free-Float 72,9%
Chart GIMV NV
Duration : Period :
Gimv NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GIMV NV
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 55,20 €
Average target price 54,00 €
Spread / Average Target -2,17%
Managers and Directors
Koen Dejonckheere Chief Executive Officer & Director
Kristof Vande Capelle Chief Financial Officer
Hilde Laga Chairman
Vincent van Bueren Manager-Compliance & ESG
Bart van Hooland Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GIMV NV10.40%1 712
BLACKSTONE INC.98.57%84 494
KKR & CO. INC.74.31%41 150
LEGAL & GENERAL PLC3.23%22 543
THE CARLYLE GROUP INC.70.17%19 100
AMUNDI15.04%18 115